Synaptic vesicular amine transporter · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Synaptic vesicular amine transporter shows approved-linked disease relevance led by attention deficit hyperactivity disorder. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q05940. Start with attention deficit hyperactivity disorder, then reuse UniProt Q05940 as the stable protein anchor across project notes and exports.
Start with attention deficit hyperactivity disorder, then reuse UniProt Q05940 as the stable protein anchor across project notes and exports.
Synaptic vesicular amine transporter shows approved-linked disease relevance led by attention deficit hyperactivity disorder. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with attention deficit hyperactivity disorder because it currently carries approved-linked support. Linked drugs include DEXTROAMPHETAMINE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE, LISDEXAMFETAMINE DIMESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySynaptic vesicular amine transporter
Review this target as Synaptic vesicular amine transporter, mapped to UniProt Q05940. Sequence length is 514 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Synaptic vesicular amine transporter as ChEMBL target CHEMBL1893, mapped to UniProt Q05940. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Synaptic vesicular amine transporter is the right protein anchor across sources, using UniProt Q05940 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why attention deficit hyperactivity disorder is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Synaptic vesicular amine transporter |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q05940 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Synaptic vesicular amine transporter |
| UniProt Accession | Q05940 |
| Component Type | Protein |
| Sequence Length | 514 aa |
Synaptic vesicular amine transporter
Review this target as Synaptic vesicular amine transporter, mapped to UniProt Q05940. Sequence length is 514 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Synaptic vesicular amine transporter shows approved-linked disease relevance led by attention deficit hyperactivity disorder. 5 more disease programs remain visible in the same review block.
Start review with attention deficit hyperactivity disorder because it currently carries approved-linked support. Linked drugs include DEXTROAMPHETAMINE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE, LISDEXAMFETAMINE DIMESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL579217 | 10.0 | Ki | 0.1 | Clinical |
| CHEMBL576222 | 8.59 | Ki | 2.6 | Preclinical |
| CHEMBL5943183 | 8.28 | Ki | 5.2 | Preclinical |
| CHEMBL772 | 8.28 | Ki | 5.26 | Approved |
| CHEMBL772 | 8.1 | Kd | 8.0 | Approved |
| CHEMBL772 | 7.88 | IC50 | 13.2 | Approved |
| CHEMBL4205254 | 7.8 | IC50 | 16.0 | Preclinical |
| CHEMBL4207658 | 7.71 | IC50 | 19.7 | Preclinical |
| CHEMBL117785 | 7.7 | IC50 | 19.8 | Approved |
| CHEMBL4206824 | 7.55 | IC50 | 28.1 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 13 | 13 | 6.1 |
| cell-based format | 10 | 20 | 6.4 |
| assay format | 3 | 66 | 6.7 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 3 | 7.0 |